Drug Profile
Auriclosene - NovaBay Pharmaceuticals
Alternative Names: AgaDerm; AgaNase; AL-46383A; CD-07223; DCDMT; NVC-422Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator NovaBay Pharmaceuticals
- Developer Alcon; Galderma; NovaBay Pharmaceuticals
- Class Alkanesulfonic acids; Anti-infectives; Antibacterials; Antifungals; Chloramines; Skin disorder therapies; Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Catheter infections
Highest Development Phases
- Phase II/III Impetigo
- Phase II Catheter infections
- No development reported Acne; Escherichia coli infections; Klebsiella infections; Onychomycosis; Staphylococcal infections
- Discontinued Infectious conjunctivitis; Otorhinolaryngological infections
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Escherichia-coli-infections in USA
- 28 Feb 2019 No recent reports of development identified for preclinical development in Klebsiella-infections in USA
- 28 Feb 2019 No recent reports of development identified for preclinical development in Onychomycosis in USA (Topical)